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The purpose of this study was to investigate the accumulation of genetic alterations during metachronous and/or synchronous
development of multifocal low-grade superficial urothelial tumours in the same patient, by using array-based comparative genomic
hybridisation (array-CGH) and FGFR mutation analysis. We analysed 24 tumours (pTa-1 G1-2) from five patients. We had previously
identified a clonal relationship among the tumours of each patient by microsatellite analysis. This time, unsupervised hierarchical
cluster analysis revealed that the tumours from each patient were clustered together independently of the tumours from the other
patients. All of the tumours from a single patient showed a set of 2–7 identical regional or whole-arm chromosomal changes. In
addition, several individual alterations were also found. Cladistic diagrams revealed that the accumulation of genetic alterations could
not be explained by a linear model, and the existence of a hypothetical precursor cell was assumed in four patients. In some cases,
FGFR mutation seemed to occur later during multifocal tumour development. Taken together, these findings suggest that low-grade
superficial urothelial tumours accumulate minor genetic alterations during multifocal development, although these tumours are
genetically stable.
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It is now commonly accepted that solid primary cancers, including
urothelial tumours and cancer of the colon, breast, and lung, arise
due to a multistep process involving the accumulation of genetic
alterations (Hittelman, 2001; Almadori et al, 2004). It is generally
difficult to follow the chronology of genetic alterations that
accompanies growth of a human tumour due to therapeutic
intervention. Therefore, the postulated steps in the process of
carcinogenesis are almost invariably based on retrospective
comparison of the genomic alterations in tumours obtained from
different patients that are of different stages and grades. Early steps
are therefore defined as genetic alterations that are found in
tumours of all grades and at all stages, whereas late steps are only
detected in the tumours of later stage and higher grade.
Simultaneous or metachronous development of multifocal uro-
thelial tumours is a well-known characteristic of this type of
cancer. Urothelial tumours are most often (70%) superficial
cancers that can be treated endoscopically, but 60–80% of patients
suffer from at least one episode of recurrence after initial
treatment. Due to these unique properties, urothelial tumours
provide a good model for the clonal analysis and chronological
tracing of genetic alterations in human cancer.
There are two theories regarding the multifocal nature of
urothelial cancer, which are known as ‘field effect’ and ‘mono-
clonality’ (Knowles, 2006). Molecular genetic studies support the
monoclonality theory and indicate that tumour cells spread to
multiple sites by intraepithelial or intraluminal seeding (Sidransky
et al, 1992; Habuchi et al, 1993; Takahashi et al, 1998; Dalbagni
et al, 2001), while other studies have shown that field effect
underlies some multifocal urothelial tumours (Paiss et al,
2002; Jones et al, 2005). An understanding of the mechanism
leading to accumulation of genetic alterations during multifocal
tumour development may provide new prospects for both the
early detection and prevention of the recurrence of urothelial
cancer.
The existence of two distinct groups of tumours with different
clinical features is also a striking feature of urothelial cancer. More
than 70% of tumours are low-grade superficial cancers at
diagnosis. These commonly recur, but progression to muscle
invasion is relatively infrequent (10–20%) and the prognosis is
usually good. In contrast, about 20% of tumours show muscle
invasion at diagnosis, and these have a poor prognosis with o50%
survival after 5 years. Furthermore, these tumour types are also
distinct at the molecular level. Over 70% of the low-grade
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ssuperficial cancers have FGFR3 mutations versus only 10–20% of
invasive cancers, strongly suggesting that activation of FGFR3 is
one of the key genetic events underlying the development of low-
grade superficial urothelial cancer (Wu, 2005). Recent array-based
comparative genomic hybridisation (array-CGH) and SNP array
analyses have shown that DNA copy number changes are more
frequent in invasive cancer than in low-grade superficial tumours
(Primdahl et al, 2002; Blaveri et al, 2005).
These two distinct types of cancer can both be multifocal, but
the extent or pattern of clonal evolution during development
seems to differ between them. Simon et al (2001) conducted a
cytological analysis of multifocal invasive bladder cancer by
CGH. They reported that all the tumours of a single patient were
derived from a common progenitor cell and subsequently acquired
various additional genetic alterations. In the case of low-grade
superficial tumours, synchronous or metachronous lesions
obtained from the same patient are also generally reported to
show a striking degree of identity in their genetic alterations
(Takahashi et al, 1998; Zhao et al, 1999). However, previous
studies of low-grade superficial tumours focussed on a few
specific genetic changes, and did not investigate chromosomal
gains and losses throughout the entire tumour genome. By
examining more samples from each patient using array-CGH with
a higher resolution, we should be able to draw a more detailed
genetic tree and pedigree for multifocal urothelial tumours and
trace the genetic alterations that accumulate during their devel-
opment.
In this study, we used the MCG Cancer Array-800 with 800 target
bacterial artificial chromosome (BAC) clone DNAs and FGFR
mutation analysis to examine possible genetic divergence and the
presence of a genetic hierarchy during the development and
recurrence of urothelial cancer.
MATERIALS AND METHODS
Patients and tumour samples
Twenty-four physically distinct urothelial tumours of the bladder,
ureter, and renal pelvis that were obtained from five patients were
included in this study. The clinical and pathological data are
summarised in Table 1. Most of the tumour specimens were
obtained by transurethral resection (TUR). Samples were snap-
frozen and stored at  801C until the extraction of DNA. An
adjacent or deeper portion of the same tumour specimen was used
for the histopathological examination. In the case of renal pelvic or
ureteral tumours, tissue specimens were collected under direct
vision and subjected to histopathological analysis along with DNA
extraction. The location of each tumour was recorded. If a tumour
recurred at the same location less than 3 months after TUR, the
lesion was excluded because there was a high probability of
incomplete resection. Also excluded were tumour specimens that
contained more than 20% normal interstitial cells on haematoxylin
and eosin staining. All of the tumours were low-grade (grade 1–2
by 1998 WHO criteria) superficial cancers. Normal reference DNA
was obtained from peripheral blood samples in each patient.
Tumour DNA and reference DNA samples were prepared by
proteinase K digestion and phenol/chloroform extraction.
These tumours were analysed in our previous LOH study and a
clonal relationship was already defined (Takahashi et al, 1998).
Using microsatellite markers, we examined genetic alterations at
20 loci on eight chromosome arms (2q, 4p, 4q, 8p, 9p, 9q, 11p, and
17p). Completely identical LOH patterns were detected in three
patients (Patients 1, 2, and 31), while a mixture of discordant
patterns together with concordant patterns were observed in two
patients (Patients 16 and 21). Written informed consent was
obtained from each patient before surgery according to the ethical
guidelines of our university.
Array-CGH analysis
Array-CGH analysis was performed with the MCG Cancer Array-
800, which consists of B800 BACs harbouring 800 known cancer-
related genes, and is intended for diagnosis of cancer-specific copy
number aberrations (Sonoda et al, 2004). Array-CGH experiments
were carried out as described previously (Takada et al, 2005) with
minor modifications. Briefly, DpnII-restricted test DNA (tumour
DNA) and reference DNA (peripheral blood genomic DNA) were
labelled by random priming with Cy3- and Cy5-dCTP (Amersham
Biosciences, Tokyo, Japan), precipitated with ethanol in the
presence of Cot-1 DNA, redissolved in a hybridisation mixture
(50% formamide, 10% dextran sulphate, 2 standard saline citrate
(SSC), and 4% sodium dodecyl sulphate, pH 7), and denatured at
751C for 8min. After incubation at 421C for 30min, each mixture
was applied to array slides and incubated at 501C for 10min, 461C
for 10min, and 421C for 60h in a hybridisation machine
(Hybrimaster HS-300, Aloka, Tokyo, Japan). Hybridised slides
were washed once in a solution of 50% formamide and 2 SSC
(pH 7.0) for 10min at 501C, and then in 1 SSC for 10min at 421C.
After air-drying, the arrays were scanned with a GenePix 4000B
(Axon Instruments, Foster City, CA, USA), and the images thus
acquired were analysed with GenePix Pro 4.1 imaging software
(Axon Instruments). Fluorescence ratios were normalised so that
the mean of the middle third of log 2 ratios across the array was
zero. A global threshold of 70.40 defined gain or loss for all of the
BAC clone log 2 ratios. High-level amplification and homozygous
deletion were defined by a log 2 ratio of 42 and o 2,
respectively.
Analysis of array-CGH data
Among the 800 BAC clones, 17 spots were omitted from analysis
because of collation with the latest genomic data and re-evaluation
of clone design. We performed unsupervised hierarchical cluster
analysis of log 2 ratios obtained for the target BAC clones to
Table 1 Characteristic of 24 urothelial tumours of five patients
Patient Tumour Date Site
a Grade pT
FGA
b(%)
FGFR3
status
1 1 November 1994 B5 2 a 8.2 WT
2 May 1995 B1 2 a 2.4 Y375C
3 August 1996 B3 1 a 12.4 Y375C
4 October 1997 B5 1 a 3.6 Y375C
2 1 May 1997 B2 1 a 10.2 S249C
2 August 1997 B3 142 a 9.3 S249C
3 October 1997 B2 142 a 17.8 S249C
4 — B2 142 a 10.2 S249C
5 — B4 142 a 10.2 S249C
6 November 1997 P 1,2 a 9.7 S249C
7 — P 1,2 a 9.4 S249C
8 — P 1,2 a 4.8 S249C
16 1 January 1997 U 2 a 13.9 S249C
2 August 1997 B1 2 a 11.7 S249C
3 — B2 2 a 8.9 S249C
4 — B2 2 a 7.7 S249C
21 1 May 1997 B1 2 1a 15.4 Y375C
2 October 1997 B2 2 1a 10.8 Y375C
4 January 1998 B2 241 a 12.4 Y375C
5 — B2 241 a 12.3 Y375C
31 1 January 1998 B1 2 a 5.2 S249C
2 — B1 2 a 5.7 S249C
3 — B2 2 a 8.7 S249C
4 — B2 2 a 8.0 S249C
aU¼ureteral tumour; P¼renal pelvic tumour; B¼bladder tumour (the locations of
the bladder tumour were as follows: B1¼trigone; B2¼posterior wall; B3¼right
wall; B4¼left wall; B5¼anterior wall).
bFraction of genome altered.
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or different. The Ward linkage and cosine coefficient metric were
used, and results were assessed with the software program R.
Contiguous alterations were expressed as regional or whole-arm
changes by calculating the median log 2 ratio of all BAC clones
mapping to each altered region of a chromosome. A threshold of
70.30 was then applied to the median log 2 ratio to define
‘regional’ gains or losses relative to the reference sample.
FGFR3 mutation analysis
Mutations of FGFR3 were identified by direct sequencing of
tumour DNA. Three regions of interest containing the previously
identified mutations were amplified by PCR (Jebar et al, 2005)
using the following primer pairs: for exon 7, 50-AGTGGCGG
TGGTGGTGAGGGAG-30 and 50-TGTGCGTCACTGTACACCTTGC
AG-30; for exon 10, 50-CCTCAACGCCCATGTCTTT-30 and 50-GGG
AGCCCAGGCCTTTCTTG-30; and for exon 15, 50-CCGCAATGT
GCTGGTGAC-30 and 50-GGCGTCCTACTGGCATGA-30. PCR
amplicons were purified using a PCR purification kit (Qiagen,
Hilden, Germany) and then directly sequenced with the same
primers that were used for the initial PCR and the ABI Prism 310
genetic analysis system (Applied Biosystems, Warrington, UK).
RESULTS
Array-CGH analysis
A file containing the raw CGH array data is available as
Supplementary information. Among the 783 BAC clones examined
in each of 24 tumours (18792 in total), gain and loss were observed
in 567 (3.0%) and 1299 (6.9%), respectively. The most common
alterations of the chromosome arms were 9q loss (79%), 9p loss
(75%), 11p loss (67%), 20q gain (50%), 17p loss (46%), and 11q
loss (38%). Alterations of these regions were also reported in two
previous array-CGH studies of bladder cancer (Veltman et al, 2003;
Hurst et al, 2004). Homozygous deletions were observed at the
locus where clones (9p21) containing the MTAP gene and CDKN2B
(p16) gene were mapped in eight tumours of two patients, whereas
high-level amplifications were not detected.
Copy number alterations were found in a large fraction of most
tumours. The extent of genomic changes was defined as the
fraction of the genome altered (FGA), as described by Blaveri et al
(2005). Each clone was assigned a genomic distance equal to the
sum of one-half of the distance between its own centre and that of
its two neighbouring clones. The average genomic distance
between clones resulting from this calculation was B3.5Mb.
Overall, each tumour had an average 9.5% (2.5% gain and 7.0%
loss) frequency of alterations (Table 1).
Figure 1 shows the cluster dendrogram for the 24 tumours of the
five patients based on the similarity of genetic alterations detected
by array-CGH. Tumour pairs from each patient were clustered
together. One tumour was related more closely to the other
tumours from the same patient than to the tumours from any of
the other patients, suggesting that these tumour pairs were clonally
related.
All of the tumours derived from a single patient showed a set of
2–7 identical regional changes or whole-arm changes, although
several additional individual alterations were also found. Repre-
sentative array-CGH profiles are presented in Figure 2.
FGFR3 mutation analysis
Mutations of FGFR3 are strongly associated with a low tumour
grade and stage, with up to 60–70% of low-grade pTa tumours
showing these mutations (Billerey et al, 2001; van Rhijn et al, 2001;
Jebar et al, 2005). Therefore, in addition to chromosomal
alterations, FGFR3 mutations are used as a clonal marker. A total
of 23 FGFR3 mutations were found in the 24 tumours (Table 1). In
three patients (Patients 2, 16, and 31), all of their tumours had the
S249C mutation. In Patient 21, all tumours had the Y375C
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Figure 1 Hierarchical clustering of data for 24 tumours obtained from
clones in the MCG Cancer Array-800. The data are presented in a matrix
format. Each column corresponds to a single tumour, and each row
corresponds to a single clone ordered by mapping position. Gain or loss of
a clone is represented by the colour of the cells in the matrix (green
indicates gain, black is no change, and red means loss). Colour saturation is
proportional to the magnitude of the difference. The sidebars to the left of
the matrix format represent a chromosome cluster ordered from
chromosome 1 to Y. The horizontal dendrogram shows that the
associations between tumours and the length of the branches reflect the
extent of similarity between tumours. Note that each tumour from a
particular patient is more closely related to other tumours from the same
patient than to any tumours from the other patients.
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smutation. Such results suggested that the multifocal tumours of
these four patients were clonally related. In Patient 1, however,
tumours 2–4 had the Y375C mutation, while tumour 1 was WT
FGFR3. This suggests that FGFR mutation may occur later during
multifocal tumour development in some cases.
Cladistic diagrams of the accumulation of genetic
alterations during multifocal tumour development
Based on the results obtained with respect to array-CGH and
FGFR3 mutations, possible schematic pathways of the genetic
alterations that occur during the development of multifocal low-
grade superficial urothelial tumours are presented in Figure 3.
Using the theory of accumulation of genetic changes during
tumour development, we developed cytogenetic pedigrees
that reflected the accumulation of chromosomal aberrations in
each case. An apparent pattern of accumulation of genetic
alterations was detected in three patients (Patients 1, 2, and 31).
Patient 2 had tumours that were genetically stable because seven
(T1, 2, 4–8) out of eight tumours had the same pattern of
chromosomal aberrations, and only one tumour (T3) showed
additional alterations. In the remaining four patients (Patients 1,
16, 21, and 31), the accumulation of genetic alterations could not
be explained by a linear model, so a hypothetical precursor cell was
assumed. In particular, Patient 16 had tumours with diverse
additional chromosomal aberrations that were presumably
acquired from a hypothetical precursor cell. In the light of these
results, the possibility was suggested that undetected tumour
cells already existed at the time of first presentation in Patients
1, 16, and 21.
- -
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Figure 2 Graphical representation of array-CGH analysis of tumours from Patients 2 and 16 (whole genome). Vertical lines indicate the boundaries of the
chromosomes. (A) In Patient 2, a concordant pattern was found in 4q32-35, 6q15-22, 9p21-24, 9q, 11p, 17p (loss) and 20q (gain). A later tumour (T3) had
additional genetic alterations (2p, 2q (gain)). (B) In Patient 16, several discordant patterns were found in 11p, 13q22-tel, 17p, 18q, and 20p. Average log 2
ratios were plotted for all clones at the chromosome positions. Thresholds for gain or loss are shown within log 2 ratios of 0.3 and  0.3, respectively.
Arrows indicate the differences of the pattern of chromosomal aberrations between tumour pairs. T¼tumour; Chr¼chromosome.
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sComparison of array-CGH and PCR-based microsatellite
analysis
Both the microsatellite data and the CGH array results are available
as Supplementary information. The loci of the 20 microsatellite
markers used in the previous study did not correspond exactly
with the target DNAs for array-CGH. Among the microsatellite
markers used in the previous study, 12 markers for which the
distance to the nearest spot on the array was less than 1Mb were
selected to compare the results of the two methods. Of 184
informative microsatellite analyses using the 12 markers, 107
showed LOH. Overall, 124 out of 184 informative microsatellite
analyses (67.3%) matched the results of array-CGH. Among the
107 sites of LOH, 61 (57.0%) were detected as gains or losses by
array-CGH. Thus, the results of the array-CGH and microsatellite
analyses did not match closely, probably because the loci of most
microsatellite markers did not correspond with the spots on the
array. In addition, the different results have been related to
differences of the assay method because microsatellite analysis
involves amplification, while array-CGH does not.
DISCUSSION
Chronological analyses of multifocal tumours have suggested that
the clinical presentation of each lesion may not necessarily be
correlated with the order in which genetic alterations occur or with
biological tumour development (Habuchi, 2005). In the present
study, cladistic diagrams revealed that the genetic aberrations of
individual tumours could not be explained by a linear model, and
the existence of a hypothetical precursor cell was assumed in
four of our five patients. In addition, we found that the order in
which tumours presented clinically was not the same as the
order of development in Patient 2. Interestingly, van Tilborg et al
(2000) reported similar findings to these in an LOH-based analysis
of multifocal bladder cancer. A tumour with additional genetic
alterations may develop earlier than a tumour without such
alterations, even though both lesions are derived from the
same precursor cell. This finding may provide interesting
information for the development of appropriate treatments and
surgical strategies. According to a recent meta-analysis, a single
instillation of a chemotherapy agent immediately after TUR
significantly reduces the recurrence rate during the first and
second years in patients with stage Ta/T1 bladder cancer
(Oosterlinck et al, 2005). This effect has been explained by the
prevention of tumour seeding at the time of TUR. However, there
is some evidence that relapse occurs at a similar rate in both the
intravesical chemotherapy and observation groups after this early
period (Oosterlinck et al, 2005). This may be explained by the
concept that some patients with multifocal low-grade tumours
already have undetected tumour cells at various sites at the time of
first presentation due to intraluminal seeding or intraepithelial
spread.
Studies based on molecular genetics have suggested a mono-
clonal origin for multifocal urothelial tumours, while other studies
have clearly shown an independent origin for some multifocal
cancers. Thus, both of these mechanisms appear to operate during
multifocal tumour development. Most of the previous studies
investigated advanced and high-grade cancers, while few studies
have focussed on low-grade superficial tumours. Several reports
have indicated that superficial multifocal bladder tumours are
most likely to be of monoclonal origin (Takahashi et al, 1998; Li
and Cannizzaro, 1999; Louhelainen et al, 2000). For this study, we
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Figure 3 Evolutionary genetic tree depicting the relationship between the multiple tumours of each patient.
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schose tumours that appeared to be clonal from the results of our
previous LOH study. Cluster analysis showed that each tumour
was more closely related to the other tumours of the same patient
than to any of the tumours from the other patients (Figure 1), and
cladistic diagrams revealed how these tumours evolved (Figure 3).
Our results suggested that the tumours of most patients were
clonally related.
Progression of genomic instability that correlates with the stage
of a tumour has been described (Koed et al, 2005), while a study
indicated that certain chromosomal areas are frequently altered
during the progression of bladder cancer (Primdahl et al, 2002).
When Koed et al (2005) studied at least two tumours of different
stages from the same patient, they found that allelic imbalances
were more common in later stage (T2-4) tumours than in earlier
stage (Ta-1) tumours. In the present study, low-grade superficial
tumours (22 were pTa and 2 were pT1) had a 9.5% average
frequency of alterations. This was consistent with the findings of
Blaveri et al (2005), who showed that low grade pTa tumours had a
much lower FGA (median: 8%) than pT1 tumours (27%) or those
with muscle invasion (18%). Additional genetic alterations occur
relatively infrequently, and the overall FGA does not change
dramatically during multifocal tumour development (Table 1).
Although low-grade urothelial tumours accumulate minor genetic
alterations during multifocal development, the extent of such
alterations is small relative to the entire genome and these lesions
are genetically stable. Furthermore, the majority of the additional
genetic alterations does not affect the biological behaviour of these
tumours and might not confer any survival advantage on the
tumour cells. Our data are consistent with the view that deletions
involving chromosome 9 and mutations of FGFR3 occur early in
the development of low-grade papillary urothelial tumours
(Knowles, 2006). Interestingly, these alterations sometimes occur
later during multifocal tumour development (e.g. Patient 1), so the
patterns of accumulation of genetic alterations seem to vary among
tumour clones.
The array-CGH method has made a significant impact on cancer
cytogenetics. Quantitative measurement of DNA copy numbers
across the genome has revealed various oncogenes (Tanami et al,
2005) or tumour suppressor genes (Takada et al, 2005, 2006) that
had not been detected by earlier techniques. In addition, the higher
resolution of array-CGH has allowed precise mapping of the
boundaries of the gained and lost regions, thereby helping to
elucidate the clonal relationship between multifocal tumours
(Shelley Hwang et al, 2004; Wa et al, 2005). In conclusion, we
investigated the genetic alterations that occur during the develop-
ment of multifocal low-grade superficial urothelial tumours by
using array-CGH, and assessed the mechanism underlying the
heterotopic recurrence of urothelial cancer. Our results indicated
that array-CGH is a powerful tool for the genetic analysis of
multifocal urothelial tumours.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Almadori G, Bussu F, Cadoni G, Galli J, Rigante M, Artuso A, Maurizi M
(2004) Multistep laryngeal carcinogenesis helps our understanding of the
field cancerisation phenomenon: a review. Eur J Cancer 40: 2383–2388
Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S,
Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC,
Bonaventure J, Zafrani ES, van der Kwast T, Thiery JP, Radvanyi F (2001)
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa)
tumors. Am J Pathol 158: 1955–1959
Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T,
Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM (2005) Bladder
cancer stage and outcome by array-based comparative genomic
hybridization. Clin Cancer Res 11: 7012–7022
Dalbagni G, Ren ZP, Herr H, Cordon-Cardo C, Reuter V (2001) Genetic
alterations in tp53 in recurrent urothelial cancer: a longitudinal study.
Clin Cancer Res 7: 2797–2801
Habuchi T (2005) Origin of multifocal carcinomas of the bladder and upper
urinary tract: molecular analysis and clinical implications. Int J Urol 12:
709–716
Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O
(1993) Metachronous multifocal development of urothelial cancers by
intraluminal seeding. Lancet 342: 1087–1088
Hittelman WN (2001) Genetic instability in epithelial tissues at risk for
cancer. Ann NY Acad Sci 952: 1–12
Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA (2004)
High-resolution analysis of genomic copy number alterations in bladder
cancer by microarray-based comparative genomic hybridization. Onco-
gene 23: 2250–2263
Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA
(2005) FGFR3 and Ras gene mutations are mutually exclusive genetic
events in urothelial cell carcinoma. Oncogene 24: 5218–5225
Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S,
Cocco A, Cheng L (2005) Molecular evidence supporting field effect in
urothelial carcinogenesis. Clin Cancer Res 11: 6512–6519
Knowles MA (2006) Molecular subtypes of bladder cancer: Jekyll and Hyde
or chalk and cheese? Carcinogenesis 27: 361–373
Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Moller K, von der
Maase H, Orntoft TF (2005) High-density single nucleotide polymorph-
ism array defines novel stage and location-dependent allelic imbalances
in human bladder tumors. Cancer Res 65: 34–45
Li M, Cannizzaro LA (1999) Identical clonal origin of synchronous and
metachronous low-grade, noninvasive papillary transitional cell carci-
nomas of the urinary tract. Hum Pathol 30: 1197–1200
Louhelainen J, Wijkstrom H, Hemminki K (2000) Allelic losses demonstrate
monoclonality of multifocal bladder tumors. Int J Cancer 87: 522–527
Oosterlinck W, Solsona E, Akaza H, Busch C, Goebell PJ, Malmstrom PU,
Ozen H, Sved P (2005) Low-grade Ta (noninvasive) urothelial carcinoma
of the bladder. Urology 66: 75–89
Paiss T, Wohr G, Hautmann RE, Mattfeldt T, Muller M, Haeussler J, Vogel
W (2002) Some tumors of the bladder are polyclonal in origin. J Urol 167:
718–723
Primdahl H, Wikman FP, von der Maase H, Zhou XG, Wolf H, Orntoft TF
(2002) Allelic imbalances in human bladder cancer: genome-wide
detection with high-density single-nucleotide polymorphism arrays.
J Natl Cancer Inst 94: 216–223
Shelley Hwang E, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE,
Esserman LJ, Waldman FM (2004) Clonality of lobular carcinoma in situ
and synchronous invasive lobular carcinoma. Cancer 100: 2562–2572
Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC,
Vogelstein B (1992) Clonal origin bladder cancer. N Engl J Med 326:
737–740
Simon R, Eltze E, Schafer KL, Burger H, Semjonow A, Hertle L, Dockhorn-
Dworniczak B, Terpe HJ, Bocker W (2001) Cytogenetic analysis of
multifocal bladder cancer supports a monoclonal origin and intraepi-
thelial spread of tumor cells. Cancer Res 61: 355–362
Sonoda I, Imoto I, Inoue J, Shibata T, Shimada Y, Chin K, Imamura M,
Amagasa T, Gray JW, Hirohashi S, Inazawa J (2004) Frequent silencing of
low density lipoprotein receptor-related protein 1B (LRP1B) expression
by genetic and epigenetic mechanisms in esophageal squamous cell
carcinoma. Cancer Res 64: 3741–3747
Takada H, Imoto I, Tsuda H, Nakanishi Y, Ichikura T, Mochizuki H,
Mitsufuji S, Hosoda F, Hirohashi S, Ohki M, Inazawa J (2005) ADAM23, a
possible tumor suppressor gene, is frequently silenced in gastric cancers
by homozygous deletion or aberrant promoter hypermethylation.
Oncogene 24: 8051–8060
Takada H, Imoto I, Tsuda H, Nakanishi Y, Sakakura C, Mitsufuji S,
Hirohashi S, Inazawa J (2006) Genomic loss and epigenetic silencing of
very-low-density lipoprotein receptor involved in gastric carcinogenesis.
Oncogene 25: 6554–6562
Array-CGH of multifocal urothelial cancers
H Kawanishi et al
265
British Journal of Cancer (2007) 97(2), 260–266 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sTakahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T,
Yoshida O (1998) Clonal and chronological genetic analysis of multi-
focal cancers of the bladder and upper urinary tract. Cancer Res 58:
5835–5841
Tanami H, Tsuda H, Okabe S, Iwai T, Sugihara K, Imoto I, Inazawa J (2005)
Involvement of cyclin D3 in liver metastasis of colorectal cancer, revealed
by genome-wide copy-number analysis. Lab Invest 85: 1118–1129
van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH,
Zwarthoff EC (2001) The fibroblast growth factor receptor 3 (FGFR3)
mutation is a strong indicator of superficial bladder cancer with low
recurrence rate. Cancer Res 61: 1265–1268
van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH,
Zwarthoff EC (2000) Molecular evolution of multiple recurrent cancers of
the bladder. Hum Mol Genet 9: 2973–2980
Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S,
Carroll P, Kuo WL, Pinkel D, Albertson D, Cordon-Cardo C, Jain AN,
Waldman FM (2003) Array-based comparative genomic hybridization
for genome-wide screening of DNA copy number in bladder tumors.
Cancer Res 63: 2872–2880
Wa CV, DeVries S, Chen YY, Waldman FM, Hwang ES (2005) Clinical
application of array-based genomic hybridization to define the relation-
ship between multiple synchronous tumors. Mod Pathol 18: 591–597
Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat
Rev Cancer 5: 713–725
Zhao J, Richter J, Wagner U, Roth B, Schraml P, Zellweger T, Ackermann D,
Schmid U, Moch H, Mihatsch MJ, Gasser TC, Sauter G (1999)
Chromosomal imbalances in noninvasive papillary bladder neoplasms
(pTa). Cancer Res 59: 4658–4661
Array-CGH of multifocal urothelial cancers
H Kawanishi et al
266
British Journal of Cancer (2007) 97(2), 260–266 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s